产品介绍：
产品说明
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
生化/生理作用
伏立康唑是用于治疗严重真菌感染的抗真菌药。伏立康唑通过抑制 CYP450 依赖性 14-α甾醇脱甲基酶来抑制麦角固醇合成，从而导致真菌细胞膜中的麦角固醇减少。
包装
Unit quantity: 120 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
注意
Please find SDS provided by EDQM here..
其他说明
Sales restrictions may apply.
基本信息
| 经验(实验)分子式 | C16H14F3N5O |
| 分子量 | 349.31 |
| MDL编号 | MFCD00905717 |
| PubChem化学物质编号 | 329831401 |
| NACRES | NA.24 |
产品性质
| 等级 | pharmaceutical primary standard |
| manufacturer/tradename | EDQM |
| application(s) | pharmaceutical (small molecule) |
| 格式 | neat |
| 储存温度 | 2-8℃ |
| SMILES string | C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F |
| InChI | 1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1 |
| InChI key | BCEHBSKCWLPMDN-MGPLVRAMSA-N |
安全信息
| 象形图 |   |
| 警示用语： | Danger |
| 危险声明 | H301 - H341 - H351 - H361 - H371 - H372 - H373 - H412 |
| 预防措施声明 | P201 - P202 - P260 - P264 - P273 - P301 + P310 |
| 危险分类 | Acute Tox. 3 Oral - Aquatic Chronic 3 - Carc. 2 - Muta. 2 - Repr. 2 - STOT RE 1 - STOT RE 2 Oral - STOT SE 2 Oral |
| 靶器官 | Eyes |
| 储存分类代码 | 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
